We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK Department of Health (DoH) is urging all medicines and medical technology manufacturers to use the GS1 autoidentification and data capturing (AIDC) system for tracking products supplied to the English National Health System (NHS).
A recent discussion paper issued by Health Canada proposes a new system of “progressive” licensing of prescription drugs to improve information on safety and efficacy after they are approved for use.
Trade representatives from the U.S. and South Korea April 1 successfully concluded months-long negotiations on a fair trade agreement (FTA) that includes provisions to increase access to innovative medicines and medical technologies and lengthen patent exclusivity for original products.
Advocacy group Public Citizen has asked the FDA to ban what it calls a "dangerous, misleading" TV ad for Pfizer's arthritis pain medicine Celebrex. Read More
Driven by strong product performance of its generic business line, Mylan Pharmaceuticals modified financial results for fiscal 2007, increasing its diluted earnings per share guidance range, the company said April 10.
Factors such as geographic location, a hospital's procedural volume or a patient's insurance type have major effects on the type of stent treatment patients receive, according to a recent study from the Mayo Clinic.
Omnicare has entered into a contract with Cardinal Health’s repackaging unit following the long-term care pharmacy’s closure of its Heartland operation, the companies recently announced.
Canadian drugs sold to consumers in the U.S. via the internet last year were half what they were the year before, according to IMS Health researchers who blamed a variety of market factors for the dramatic plunge in sales volume.
Boston Scientific’s “largest driver in financial performance” is the drug-eluting stent market, which has been softening, with “no rebound” seen yet, Chief Operating Officer Paul LaViolette said at the Lehman Brothers 10th Annual Global Healthcare Conference.